Aclarion Announces Pricing of Registered Direct Offering of Common Stock Priced at the MarketBROOMFIELD, CO - January 30, 2025 (NEWMEDIAWIRE) - Aclarion, Inc., (“Aclarion” or the “Company”) (Nasdaq: ACON, ACONW), a healthcare technology company that is leveraging biomarkers and proprietary augmented intelligence (AI) algorithms to help physicians identify the location of chronic low back pain, today announced that it has agreed to sell 506,803 shares of its common stock at a price per share of $9.25 in a registered direct offering priced at the market. All of the shares of common stock in the offering are being sold by Aclarion. The closing of the offering is expected to take place on or about January 31, 2025, subject to the satisfaction of customary closing conditions.
Aclarion Announces Pricing of Registered Direct Offering of Common Stock Priced at the MarketSearch for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
Aclarion Announces Revised Split Ratio and Timing for Reverse Stock SplitSearch for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
Aclarion Announces Revised Split Ratio and Timing for Reverse Stock SplitBROOMFIELD, CO - January 28, 2025 (NEWMEDIAWIRE) - Aclarion, Inc., (“Aclarion” or the “Company”) (Nasdaq: ACON, ACONW), a healthcare technology company that is leveraging biomarkers and proprietary augmented intelligence algorithms to help physicians identify the location of chronic low back pain, today announced revised timing and a revised split ratio for its pending reverse stock split of its common stock.
Aclarion Announces Reverse Stock SplitSearch for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
Aclarion Announces Reverse Stock SplitBROOMFIELD, CO - January 24, 2025 (NEWMEDIAWIRE) - Aclarion, Inc., (“Aclarion” or the “Company”) (Nasdaq: ACON, ACONW), a healthcare technology company that is leveraging biomarkers and proprietary augmented intelligence algorithms to help physicians identify the location of chronic low back pain, today announced that effective before market open on Wednesday, January 29, 2025, it will complete a 1-for-370 reverse stock split of its common stock.
Aclarion Announces Closing of $14.4 Million Public Offering of Common Stock and WarrantsSearch for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
Aclarion Announces Closing of $14.4 Million Public Offering of Common Stock and WarrantsBROOMFIELD, CO - January 17, 2025 (NEWMEDIAWIRE) - Aclarion, Inc. (“Aclarion” or the “Company”) (Nasdaq: ACON, ACONW), a healthcare technology company that is leveraging biomarkers and proprietary augmented intelligence (AI) algorithms to help physicians identify the location of chronic low back pain, today announced the closing of an underwritten public offering of 100,000 shares of common stock and 143,900,000 pre-funded warrants with each share of common stock and each pre-funded warrant accompanied by (i) a series A common warrant to purchase one (1) common share at an exercise price of $0.20 per share and (ii) a series B common warrant to purchase one (1) common share at an exercise price of $0.20 per share. The combined public offering price of each share of common stock together with the accompanying series A and series B common warrants is $0.10, and the combined public offering price of each pre-funded warrant together with the accompanying series A and series B common warrants is $0.09999. In addition, the Company granted to the underwriter a 45 day option to purchase up to an additional 21,000,000 shares of its common stock (or pre-funded warrants), at the public offering price, less underwriting discounts and commissions, and up to an additional 21,000,000 series A common warrants and up to an additional 21,000,000 series B common warrants at a nominal price to cover over-allotment sales. The underwriter exercised its option to purchase 21,000,000 series A common warrants and 21,000,000 series B common warrants. All shares of common stock, pre-funded warrants, series A common warrants and series B common warrant were sold by Aclarion. The closing of the public offering occurred on January 16, 2025.
Aclarion Announces Pricing of $14.4 Million Public Offering of Common Stock and WarrantsSearch for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
Aclarion Announces Pricing of $14.4 Million Public Offering of Common Stock and WarrantsBROOMFIELD, CO - January 15, 2025 (NEWMEDIAWIRE) - Aclarion, Inc. (“Aclarion” or the “Company”) (Nasdaq: ACON, ACONW), a healthcare technology company that is leveraging biomarkers and proprietary augmented intelligence (AI) algorithms to help physicians identify the location of chronic low back pain, today announced the pricing of an underwritten public offering of approximately 144,000,000 shares of common stock (or pre-funded warrants in lieu thereof) with each share of common stock (or pre-funded warrant) accompanied by (i) a series A common warrant to purchase one (1) common share at an exercise price of $0.20 per share and (ii) a series B common warrant to purchase one (1) common share at an exercise price of $0.20 per share. The combined public offering price of each share of common stock together with the accompanying series A and series B common warrants is $0.10, and the combined public offering price of each pre-funded warrant together with the accompanying series A and series B common warrants is $0.09999. The Company also granted the underwriter a 45 day option to purchase up to 21,000,000 additional shares of common stock (or pre-funded warrants), up to 21,000,000 series A common warrants and up to 21,000,000 series B common warrants, to cover over-allotments. The closing of the public offering is expected to occur on or about January 16, 2025, subject to the satisfaction of customary closing conditions.
Aclarion Announces Pricing of Registered Direct Offering of Common Stock Priced at the MarketSearch for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
Aclarion Announces Pricing of Registered Direct Offering of Common Stock Priced at the MarketBROOMFIELD, CO - (NewMediaWire) - January 3, 2025 - Aclarion, Inc., (“Aclarion” or the “Company”) (Nasdaq: ACON, ACONW), a healthcare technology company that is leveraging biomarkers and proprietary augmented intelligence (AI) algorithms to help physicians identify the location of chronic low back pain, today announced that it has agreed to sell 3,380,276 shares of its common stock at a price per share of $0.142 in a registered direct offering priced at the market. All of the shares of common stock in the offering are being sold by Aclarion. The closing of the offering is expected to take place on or about January 6, 2025, subject to the satisfaction of customary closing conditions.
Aclarion to Present at the Virtual Investor Summit Microcap Event on November 21stBROOMFIELD, CO / ACCESSWIRE / November 14, 2024 / Aclarion, Inc., ("Aclarion" or the "Company") (Nasdaq:ACON)(Nasdaq:ACONW), a healthcare technology company that is leveraging biomarkers and proprietary augmented intelligence (AI) algorithms to help physicians identify the location of chronic low back pain, today announced its participation at the upcoming Virtual Investor Summit Microcap Event on November 21st. The Company will be available for 1-on-1 meetings throughout the day in addition to its formal presentation.
Aclarion's Nociscan AI Plays Key Role in Advanced Understanding of Modic ChangesSearch for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
Aclarion Provides Corporate Update on Nociscan AI Technology MilestonesSearch for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
Aclarion, Inc.’s (NASDAQ: ACON) Emerging Role in the Back Pain Management SectorAs the healthcare technology sector advances, companies are making significant strides in addressing widespread health challenges. One area experiencing notable innovation is the diagnosis and management of chronic low back pain (cLBP), a condition that affects millions globally and incurs substantial healthcare costs. Aclarion, Inc. (
NASDAQACON) is emerging as a key player in this field with its groundbreaking Nociscan platform.
Aclarion Announces Completion of First Nociscan Exams in LIFEHAB TrialInitial LIFEHAB Enrolled Patients Receive Nociscan Exams to Help Evaluate How Biomarkers in the Discs of the Lumbar Spine Correspond With Treatment Response
Aclarion Launches Surgeon Partnership to Apply Nociscan's AI Technology to Personal Injury and Workers Compensation MarketSearch for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
Launches Second Clinical Utility and Economic (CLUE) Trial Site With First Surgeon in New JerseySearch for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
Aclarion to Present at August 20th Virtual Investor Summit Microcap EventSearch for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
Aclarion Announces First Commercial Agreement in MichiganSearch for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
Aclarion Hits Another Key Milestone by Adding Vitality - Third Major Payer to Cover Nociscan in Greater UKSearch for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
Aclarion Achieves Milestone With Key Second Payer Coverage of Nociscan by Aviva Throughout Greater London, UKSearch for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
Aclarion Announces Initial Payer Coverage of Nociscan by AXA Throughout Greater London, UKSearch for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
